<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00450749</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00857</org_study_id>
    <secondary_id>NCI-2009-00857</secondary_id>
    <secondary_id>MSKCC-06118</secondary_id>
    <secondary_id>MDA-CC-2006-0388</secondary_id>
    <secondary_id>CDR0000653464</secondary_id>
    <secondary_id>CDR0000532938</secondary_id>
    <secondary_id>06-118</secondary_id>
    <secondary_id>2006-0388</secondary_id>
    <secondary_id>MDA04-3-01</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>N01CN35159</secondary_id>
    <nct_id>NCT00450749</nct_id>
  </id_info>
  <brief_title>Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer</brief_title>
  <official_title>Phase II Placebo Controlled Trial of Preoperative Lycopene Supplementation in Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well different doses of lycopene work in treating
      patients undergoing radical prostatectomy for prostate cancer. The use of lycopene, a
      substance found in tomatoes, may keep prostate cancer from growing or coming back after
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Compare the differences in tissue concentrations of lycopene in patients with prostate
      cancer undergoing radical prostatectomy treated with different doses of neoadjuvant lycopene
      supplementation.

      II. Compare the change in serum lycopene concentration from baseline and at 4-7 weeks in
      patients treated with different doses of lycopene.

      SECONDARY OBJECTIVES:

      I. Determine the effect of this treatment in down-regulating 5-alpha-reductase activity by
      measuring the change in the ratio of testosterone (T) to dihydrotestosterone (DHT) in serum
      at baseline and at 4-7 weeks and the ratio of T:DHT in prostatic surgical tissue
      post-treatment.

      II. Determine the effect of this treatment in attenuating baseline blood serum concentrations
      of total prostate-specific antigen (PSA), free PSA, and human kallikrein 2 in these patients.

      III. Determine the effect of this treatment on growth potential by examining post-treatment
      radical prostatectomy tissue specimens for proliferative index (PI) by Ki-67 expression,
      apoptotic index (AI) by TUNEL assay, and PI:AI ratio in these patients.

      IV. Determine the effect of this treatment in modulating putative biomarkers of lycopene
      efficacy, including serum concentrations of insulin-like growth factor (IGF)-1 and IGF
      binding protein-3, lymphocyte oxidative DNA damage capacity by Comet assay, and GST-pi
      expression in prostatic tissue from these patients.

      V. Compare the histological effect of different doses of lycopene on putative prognostic
      features, including the presence and extent of high-grade prostatic intraepithelial
      neoplasia, prostatitis, total tumor volume, local invasion (vascular and lymphatic, capsular,
      seminal vesicle), pathologic stage, Gleason score, surgical margins, and lymph node status in
      these patients.

      VI. Determine the effect of this treatment in modulating the RNA expression of
      androgen-related genes by microarray analysis in these patients.

      OUTLINE:

      This is a randomized, placebo-controlled, double-blind, multicenter study. Patients are
      stratified according to participating center. Patients are randomized to 1 of 3 treatment
      arms.

      ARM I: Patients receive placebo orally (PO) once daily (QD) for 4-7 weeks, and then undergo
      radical prostatectomy.

      ARM II: Patients receive low-dose lycopene PO QD for 4-7 weeks, and then undergo radical
      prostatectomy.

      ARM III: Patients receive high-dose lycopene PO QD for 4-7 weeks, and then undergo radical
      prostatectomy.

      Tumor samples are collected from prostatectomy for laboratory studies, including GST-pi
      expression by immunohistochemistry; histological analysis; microarray analysis of
      androgen-related genes; ratio of testosterone (T) to dihydrotestosterone (DHT); Ki-67
      expression; and lycopene tumor-concentration measurement.

      Patients undergo blood collection at baseline, week 4, and week 7 for laboratory studies,
      including serum lycopene concentration measurement; level of T or DHT by high-performance
      liquid chromatography/tandem mass spectrometry (HPLC/MS/MS) analysis; serum concentrations of
      total prostate-specific antigen (PSA), free PSA, and human kallikrein 2; lymphocyte oxidative
      DNA damage capacity; and serum concentrations of insulin-like growth factor (IGF)-1 and IGF
      binding protein-3 by radioimmunological assay.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of Lycopene in Prostatic Surgical Tissue</measure>
    <time_frame>At 4-7 weeks</time_frame>
    <description>Total tissue lycopene concentrations in radical prostatectomy specimens in participants receiving 6 weeks (± 1 week) of preoperative supplementation with 60 mg/day lycopene, 30 mg/day lycopene, or placebo. Concentration of lycopene in prostatic surgical tissue calculated using the high-performance liquid chromatography (HPLC) method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum Lycopene Concentration</measure>
    <time_frame>Baseline and at 4-7 weeks</time_frame>
    <description>The differences in the mean of the 6 week (± 1 week) serum lycopene concentrations after adjusting for baseline serum lycopene concentrations calculated between the three arms, together with 95% confidence intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of Testosterone (T) to Dihydrotestosterone (DHT) in Serum</measure>
    <time_frame>Baseline and at 4-7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of T:DHT in Prostatic Surgical Tissue</measure>
    <time_frame>At 4-7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Total Prostate-specific Antigen (PSA), Free PSA, and Human Kallikrein 2</measure>
    <time_frame>Baseline and at 4-7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth Potential Assessed by the Ratio of Proliferation (Ki-67):Apoptosis (TUNEL) in Prostatic Surgical Tissue</measure>
    <time_frame>At 4-7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Insulin-like Growth Factor (IGF)-1 and IGF Binding Protein-3</measure>
    <time_frame>At baseline and at 4-7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte Oxidative DNA Damage Capacity as Measured by Comet Assay</measure>
    <time_frame>At baseline and at 4-7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of GST-pi in Prostatic Surgical Tissue</measure>
    <time_frame>At 4-7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological Characteristics of Prostatic Surgical Tissue</measure>
    <time_frame>At 4-7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modulation of Expression of Androgen-related Genes as Measured by Microarray in Prostatic Surgical Tissue</measure>
    <time_frame>At 4-7 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <condition>Stage I Prostate Cancer</condition>
  <condition>Stage II Prostate Cancer</condition>
  <condition>Stage III Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo PO QD for 4-7 weeks, and then undergo radical prostatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (low-dose lycopene)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive low-dose lycopene PO QD for 4-7 weeks, and then undergo radical prostatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (high-dose lycopene)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive high-dose lycopene PO QD for 4-7 weeks, and then undergo radical prostatectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (placebo)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo radical prostatectomy</description>
    <arm_group_label>Arm I (placebo)</arm_group_label>
    <arm_group_label>Arm II (low-dose lycopene)</arm_group_label>
    <arm_group_label>Arm III (high-dose lycopene)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (placebo)</arm_group_label>
    <arm_group_label>Arm II (low-dose lycopene)</arm_group_label>
    <arm_group_label>Arm III (high-dose lycopene)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lycopene</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (low-dose lycopene)</arm_group_label>
    <arm_group_label>Arm III (high-dose lycopene)</arm_group_label>
    <other_name>all-trans-Lycopene</other_name>
    <other_name>Lyc-O-Mato</other_name>
    <other_name>LYCO</other_name>
    <other_name>psi,psi-Carotene</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria:

          -  Creatinine normal

          -  Biopsy-confirmed adenocarcinoma of the prostate

          -  Localized disease

          -  Planned radical prostatectomy

          -  ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%

          -  WBC &gt;= 3,000/mm^3

          -  Platelet count &gt;= 100,000/mm^3

          -  Bilirubin normal

          -  AST and ALT =&lt; 2.5 times upper limit of normal

          -  Fertile patients must use effective barrier contraception

          -  No other invasive cancer (except nonmelanoma skin cancer) within the past 2 years

          -  Patients who received curative treatment and have shown no evidence of recurrence
             within the past 2 years are eligible

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biological composition to lycopene (e.g., other carotenoids, including lutein and
             beta-carotene)

          -  More than 30 days since prior regular (&gt; once weekly) lycopene supplementation (&gt;= 15
             mg/day) and meets the following criteria: no more than 2 servings of tomato sauce,
             juice, or soup per week; no more than 4 servings of grapefruit, raw tomato, or
             watermelon per week

          -  Must not consume 1 serving of tomato sauce, juice, or soup per week AND more than 2
             servings of grapefruit, raw tomato, or watermelon per week

          -  More than 30 days since prior and no concurrent investigational medication

          -  No concurrent chemotherapy, radiotherapy, hormonal therapy, or immunotherapy

          -  No history of allergy to foods containing lycopene (e.g., tomatoes or tomato products,
             watermelon, guava, and pink grapefruit)

          -  No concurrent uncontrolled illness including, but not limited to, any of the
             following: ongoing or active infection; symptomatic congestive heart failure; unstable
             angina pectoris; cardiac arrhythmia; psychiatric illness/social situations that would
             limit compliance with study requirements

          -  No prior therapy for prostate cancer, including radiotherapy to the prostate or
             pelvis, androgen ablation, or antiandrogen systemic therapy

          -  No other concurrent lycopene (&gt;= 15 mg/day)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Eastham</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Israel</country>
  </removed_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2007</study_first_submitted>
  <study_first_submitted_qc>March 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2007</study_first_posted>
  <results_first_submitted>March 30, 2012</results_first_submitted>
  <results_first_submitted_qc>June 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2012</results_first_posted>
  <last_update_submitted>April 23, 2014</last_update_submitted>
  <last_update_submitted_qc>April 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lycopene</mesh_term>
    <mesh_term>Carotenoids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: April 11, 2008 to April 15, 2009. All recruitment was done in a medical clinic setting, and all participants enrolled at Memorial Sloan-Kettering Cancer Center.</recruitment_details>
      <pre_assignment_details>There were eleven participants registered, one participant was excluded from the trial before assignment to groups making only ten randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I Placebo</title>
          <description>Placebo once daily for 4-7 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Arm II Low Dose Lycopene</title>
          <description>30 mg/day oral Lycopene for 4-7 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Arm III High-Dose Lycopene</title>
          <description>60 mg/day oral Lycopene for 4-7 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I Placebo</title>
          <description>Placebo once daily for 4-7 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Arm II Low Dose Lycopene</title>
          <description>30 mg/day oral Lycopene for 4-7 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Arm III High-Dose Lycopene</title>
          <description>60 mg/day oral Lycopene for 4-7 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" lower_limit="56" upper_limit="72"/>
                    <measurement group_id="B2" value="56" lower_limit="45" upper_limit="71"/>
                    <measurement group_id="B3" value="66" lower_limit="52" upper_limit="68"/>
                    <measurement group_id="B4" value="66.5" lower_limit="45" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Concentration of Lycopene in Prostatic Surgical Tissue</title>
        <description>Total tissue lycopene concentrations in radical prostatectomy specimens in participants receiving 6 weeks (± 1 week) of preoperative supplementation with 60 mg/day lycopene, 30 mg/day lycopene, or placebo. Concentration of lycopene in prostatic surgical tissue calculated using the high-performance liquid chromatography (HPLC) method.</description>
        <time_frame>At 4-7 weeks</time_frame>
        <population>Tissue samples collected from five participants for measurement of lycopene levels, representing only 50% (5 of 10) of the participants’ enrolled on-trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I Placebo</title>
            <description>Placebo once daily for 4-7 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm II Low Dose Lycopene</title>
            <description>30 mg/day oral Lycopene for 4-7 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Arm III High-Dose Lycopene</title>
            <description>60 mg/day oral Lycopene for 4-7 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Lycopene in Prostatic Surgical Tissue</title>
          <description>Total tissue lycopene concentrations in radical prostatectomy specimens in participants receiving 6 weeks (± 1 week) of preoperative supplementation with 60 mg/day lycopene, 30 mg/day lycopene, or placebo. Concentration of lycopene in prostatic surgical tissue calculated using the high-performance liquid chromatography (HPLC) method.</description>
          <population>Tissue samples collected from five participants for measurement of lycopene levels, representing only 50% (5 of 10) of the participants’ enrolled on-trial.</population>
          <units>ug/dL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sample 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.663"/>
                    <measurement group_id="O2" value="0.378"/>
                    <measurement group_id="O3" value="0.723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sample 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.165"/>
                    <measurement group_id="O2" value="0.749"/>
                    <measurement group_id="O3" value="NA">A second tissue sample was not collected.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Lycopene Concentration</title>
        <description>The differences in the mean of the 6 week (± 1 week) serum lycopene concentrations after adjusting for baseline serum lycopene concentrations calculated between the three arms, together with 95% confidence intervals.</description>
        <time_frame>Baseline and at 4-7 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Testosterone (T) to Dihydrotestosterone (DHT) in Serum</title>
        <time_frame>Baseline and at 4-7 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of T:DHT in Prostatic Surgical Tissue</title>
        <time_frame>At 4-7 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentrations of Total Prostate-specific Antigen (PSA), Free PSA, and Human Kallikrein 2</title>
        <time_frame>Baseline and at 4-7 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Growth Potential Assessed by the Ratio of Proliferation (Ki-67):Apoptosis (TUNEL) in Prostatic Surgical Tissue</title>
        <time_frame>At 4-7 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentrations of Insulin-like Growth Factor (IGF)-1 and IGF Binding Protein-3</title>
        <time_frame>At baseline and at 4-7 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lymphocyte Oxidative DNA Damage Capacity as Measured by Comet Assay</title>
        <time_frame>At baseline and at 4-7 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Expression of GST-pi in Prostatic Surgical Tissue</title>
        <time_frame>At 4-7 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Histological Characteristics of Prostatic Surgical Tissue</title>
        <time_frame>At 4-7 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modulation of Expression of Androgen-related Genes as Measured by Microarray in Prostatic Surgical Tissue</title>
        <time_frame>At 4-7 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>13 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I Placebo</title>
          <description>Placebo once daily for 4-7 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Arm II Low Dose Lycopene</title>
          <description>30 mg/day oral Lycopene for 4-7 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Arm III High-Dose Lycopene</title>
          <description>60 mg/day oral Lycopene for 4-7 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardia Arrythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Powel H Brown, MD, PhD/Professor of Medicine and Cancer Prevention</name_or_title>
      <organization>University of Texas MD Anderson Phase I/II Prevention Consortium</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

